In a case that had been closely watched across multiple industries, Illumina chose to divest Grail in the light of legal action from the European Commission and the US Federal Trade Commission.

Illumina, Inc.'s acquisition of GRAIL, Inc. was disastrous and created all kinds of problems, but the company is refocusing on its profitable core gene sequencing business. ILMN's revenue growth ...

According to the decision of the EU's Court of Justice in Luxembourg, the European Commission had no right to block the acquisition of Grail Inc. by Illumina Inc. for $7 billion. This is stated in the ...

Nearly four years after pitching for Grail, Illumina finally separated the cancer blood test developer. To expand its reach in single-cell analysis and multiomics research, Illumina acquired ...

Also Read: European Court Rules In Favor Of Illumina In Fight Against Probe Into Grail Deal, Asks Not To Pay $478M Fine Nearly four years after pitching for Grail, Illumina finally separated the ...

Illumina, Inc. (NASDAQ ... due to its controversial multi-billion dollar deal to acquire cancer test maker Grail Inc (NASDAQ:GRAL). Also NORTHAMPTON, MA / ACCESSWIRE / December 16, 2024 ...

GRAIL’s business revolves around its product, Galleri. Galleri is an early cancer detection test for people over the age of 50 who are not showing symptoms. Illumina ILMN spun off the company in ...

Illumina, Inc. (NASDAQ:ILMN) was removed from the index. Year to date, the stock has increased around 8%, underperforming iShares Core S&P Mid-Cap ETF (NYSE:IJH). The provider of DNA sequencing and ...

Grail was officially spun off from Illumina in June 2024 as the European Commission prohibited Illumina's acquisition of Grail in 2022. Grail's sole product is the Galleri Test, which is a multi ...